| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V75391 | (D-Ser(tBu)6,D-Leu7,Azagly10)-LHRH | 1926163-38-3 | (D-Ser(tBu)6,D-Leu7,Azagly10)-LHRH is an analog of luteinizing hormone-releasing hormone (LHRH). |
|
V75389 | [D-Ala6]-LH-RH | 51230-19-4 | [D-Ala6]-LH-RH is a luteinizing hormone-releasing hormone (LHRH) analog that works as a GnRH receptor agonist (activator). |
|
V75388 | GnRH-R antagonist 1 | 2826273-90-7 | GnRH-R antagonist 1 (compound 21a) is a GnRH-R antagonist (inhibitor) with good oral safety and membrane permeability. |
|
V75383 | Phoenixin-14 (PNX-14) | 1415039-79-0 | Phoenixin-14 (PNX-14) is an endogenous active isoform that produces anxiolytic effects by activating the mouse AHA GnRH system. |
|
V115806 | WAY-207024 | 872002-72-7 | WAY-207024 is an orally administered potent gonadotropin-releasing hormone receptor (GnRH-R) antagonist (human GnRH: IC50 12 nM, rat GnRH: IC50 71 nM). |
|
V2801 | ELAGOLIX | 834153-87-6 | Elagolix (formerly NBI56418; ABT620; NBI-56418; ABT-620; trade name: Orilissa) is a potent, specific, orally bioavailable, non-peptide antagonist of the gonadotropin-releasing hormone receptor (GnRHR) used for pain management. |
|
V50930 | Antide acetate | 625092-10-6 | gonadotropin-releasing hormone receptor antagonist |
|
V3881 | Elagolix sodium | 832720-36-2 | Elagolix sodium (NBI56418; ABT-620; Orilissa), the sodium salt of Elagolix, is an orally bioavailable and small molecule antagonist of the gonadotropin-releasing hormone receptor (GnRHR) (KD = 54 pM) approved on 7/23/2018 by FDA for the management of moderate to severe pain associated with endometriosis. |